We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Canagliflozin

News List

FDA Removes Amputation Boxed Warning for Canagliflozin americanpharmaceuticalreview
August 28, 2020
Based on a U.S. Food and Drug Administration (FDA) review of new data from three clinical trials, the FDA has removed the Boxed Warning about amputation risk from the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR) prescribing ...
Canagliflozin may not be associated with fracture risk in diabetes patients europeanpharmaceuticalreview
January 03, 2019
A study has found that when compared with other drugs, canagliflozin may not be associated with fractures in patients with diabetes…
J&J's Invokana becomes first FDA-approved oral diabetes drug to reduce cardiovascular event risk pharmafile
November 01, 2018
The FDA has given the go-ahead for Johnson & Johnson’s drug Invokana (canagliflozin) for use in the risk reduction of major adverse cardiovascular (CV) events, making it the “first and only oral diabetes treatment.....